The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Sagar Lonial
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
Which antigen does talquetamab target on multiple myeloma cells?
A
B
C
D
Video series
The Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” was chaired by Sagar Lonial and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Lonial opened with a welcome and introduction to T-cell-engaging bispecific antibodies and their mechanisms of action in multiple myeloma (Figure 1). Lonial also discusses the expanding treatment options in relapsed/refractory disease (Figure 2), offering insight into the targets for bispecific antibody action and their expression on myeloma cells.
Figure 1. T-cell directed bispecific antibodies: Mechanism of action*
c, fragment crystallizable region; FcRH5, Fc receptor-homolog 5; GPRC5D, G protein–coupled receptor class C group 5 member D; MM, multiple myeloma.
*Adapted from Van de Donk N, et al.1
Figure 2. Treatment options for relapsed/refractory disease in multiple myeloma*
BsAb, bispecific antibody; IMiD, immunomodulatory agent; mAb, monoclonal antibody; MoA, mechanism of action; PI, proteosome inhibitor.
*Data from Bhatt, et al.2 and Gahvari, et al.3
This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.
References
More from this series:
